search
Back to results

The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy

Primary Purpose

ISS- Idiopathic Short Stature

Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Nutritional supplementation standardized formula
Placebo
Sponsored by
Rabin Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ISS- Idiopathic Short Stature

Eligibility Criteria

5 Years - 10 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. GH treatment for at least 24 months due to idiopathic short stature (ISS)
  2. Age 5-10 years inclusive.
  3. Tanner stage 1 (gonadarche).
  4. BMI <85 percentile for age and gender.

Exclusion Criteria:

  1. SGA/ IUGR
  2. Diagnosis of GH deficiency
  3. Any known morbidity: chronic disease dysmorphic syndromes, bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems, metabolic disorders.
  4. Any known gastrointestinal problem including absorption problems.
  5. Any chronic treatment with medication that might affect appetite, weight or growth (for example SSRI's, steroids).
  6. Any eating disorders and/or psychiatric disorder
  7. Milk or other food allergies

Sites / Locations

  • Schneider children's medical centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Nutritional standardized supplementation formula.

Placebo

Arm Description

Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.

Low caloric formula (Powder added to water) without added vitamins and minerals

Outcomes

Primary Outcome Measures

height standard deviation score (SDS)
weight standard deviation score

Secondary Outcome Measures

BMI SDS
Lean body mass
muscle mass
Fat mass
Fat mass percentage

Full Information

First Posted
July 4, 2021
Last Updated
March 15, 2023
Sponsor
Rabin Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04962360
Brief Title
The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy
Official Title
The Effect of Nutritional Formula Supplementation on Linear Growth of GH Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy: a Randomized, Double- Blind, Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2021 (Actual)
Primary Completion Date
July 2025 (Anticipated)
Study Completion Date
October 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rabin Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed study is a double blind, randomized, placebo controlled study. The aim of the study is to evaluate the effect of combined growth hormone (GH) treatment &nutritional formula supplementation versus GH & placebo on growth parameters in 64 children with Idiopathic Short Stature (ISS) after the second year of GH treatment. Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the study. The randomization will be done according to gender. Participants in the intervention groups will be treated with the study formula and participants in the control group will be treated with a placebo low caloric formula (powder added to water). The study will continue for 6 months of intervention versus active placebo, with additional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the active study supplement.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ISS- Idiopathic Short Stature

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nutritional standardized supplementation formula.
Arm Type
Experimental
Arm Description
Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Low caloric formula (Powder added to water) without added vitamins and minerals
Intervention Type
Dietary Supplement
Intervention Name(s)
Nutritional supplementation standardized formula
Intervention Description
Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Low caloric formula (Powder added to water) without added vitamins and minerals
Primary Outcome Measure Information:
Title
height standard deviation score (SDS)
Time Frame
at 6 moths
Title
weight standard deviation score
Time Frame
at 6 months
Secondary Outcome Measure Information:
Title
BMI SDS
Time Frame
at 6 months
Title
Lean body mass
Time Frame
at 6 months
Title
muscle mass
Time Frame
at 6 months
Title
Fat mass
Time Frame
at 6 months
Title
Fat mass percentage
Time Frame
at 6 months
Other Pre-specified Outcome Measures:
Title
height SDS
Time Frame
at 12 months
Title
Weight SDS
Time Frame
at 12 months
Title
BMI SDS
Time Frame
at 12 months
Title
Lean body mass
Time Frame
at 12 months
Title
muscle mass
Time Frame
at 12 months
Title
fat mass
Time Frame
at 12 months
Title
fat mass percentage
Time Frame
at 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: GH treatment for at least 24 months due to idiopathic short stature (ISS) Age 5-10 years inclusive. Tanner stage 1 (gonadarche). BMI <85 percentile for age and gender. Exclusion Criteria: SGA/ IUGR Diagnosis of GH deficiency Any known morbidity: chronic disease dysmorphic syndromes, bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems, metabolic disorders. Any known gastrointestinal problem including absorption problems. Any chronic treatment with medication that might affect appetite, weight or growth (for example SSRI's, steroids). Any eating disorders and/or psychiatric disorder Milk or other food allergies
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Moshe Phillip, Prof.
Phone
972-3-9253282
Email
mosheph@clalit.org.il
First Name & Middle Initial & Last Name or Official Title & Degree
Alonah Hamou, MSc
Phone
972-39253747
Email
alonah@clalit.org.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moshe Phillip, Prof
Organizational Affiliation
Schnieder Children's Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Schneider children's medical center
City
Petah tikva
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Moshe Phillip, Prof
Phone
972-3-9253778
Email
mosheph@clalit.org.il
First Name & Middle Initial & Last Name & Degree
Naama Fish, Dr
First Name & Middle Initial & Last Name & Degree
Liora Lazar, Prof
First Name & Middle Initial & Last Name & Degree
Sharon Demol, Dr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy

We'll reach out to this number within 24 hrs